Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

21
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
21
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

491
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
491
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

464
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
464
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

421
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
421
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

27
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
27
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

696
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
696

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

A Hospital Level Analysis of 30-Day Readmission Performance for Heart Failure Patients and Long-Term Survival: Findings from Get With The Guidelines-Heart Failure.

American heart journal·2018
Same author

Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial.

Journal of the American Heart Association·2018
Same author

Home-Time After Discharge Among Patients Hospitalized With Heart Failure.

Journal of the American College of Cardiology·2018
Same author

Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy.

European journal of heart failure·2018
Same author

Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure.

JACC. Heart failure·2018
Same author

The Call for Precision Health Trials in Older Adults: One Size Does Not Fit All.

Journal of the American College of Cardiology·2018

Video Experimental Relacionado

Updated: Aug 30, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K

Inhibidores de SGLT-2 en pacientes con insuficiencia cardíaca: un metanálisis exhaustivo de cinco ensayos controlados

Muthiah Vaduganathan1, Kieran F Docherty2, Brian L Claggett1

  • 1Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Lancet (London, England)
|August 30, 2022
PubMed
Resumen
Este resumen es generado por máquina.

Los inhibidores del cotransportador de sodio-glucosa 2 (SGLT2) reducen significativamente la mortalidad cardiovascular y las hospitalizaciones por insuficiencia cardíaca en una amplia gama de pacientes. Estos hallazgos apoyan a los inhibidores de SGLT2 como una terapia fundamental para la insuficiencia cardíaca, independientemente de la fracción de eyección.

Más Videos Relacionados

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.6K

Videos de Experimentos Relacionados

Last Updated: Aug 30, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.6K

Área de la Ciencia:

  • Cardiología
  • Farmacología
  • Ensayos clínicos

Sus antecedentes:

  • Se recomiendan inhibidores de SGLT2 para la insuficiencia cardíaca con fracción de eyección reducida.
  • Sus beneficios en pacientes con fracciones de eyección más altas están menos establecidos.
  • Los grandes ensayos como DELIVER y EMPEROR-Preserved abordan esta brecha de conocimiento.

Objetivo del estudio:

  • Realizar un metanálisis de los ensayos con inhibidores de SGLT2 en la insuficiencia cardíaca.
  • Para evaluar su eficacia en diferentes rangos de fracción de eyección.
  • Evaluar el impacto en la mortalidad cardiovascular y las hospitalizaciones por insuficiencia cardíaca.

Principales métodos:

  • Metaanálisis preespecificado de los ensayos DELIVER y EMPEROR-Conservados.
  • Se han incluido los ensayos DAPA-HF, EMPEROR-Reduced y SOLOIST-WHF.
  • Metaanálisis de efectos fijos utilizando definiciones armonizadas de puntos finales.

Principales resultados:

  • Los inhibidores de SGLT2 redujeron la muerte cardiovascular compuesta o la hospitalización por insuficiencia cardíaca (HR 0, 77).
  • Se observaron reducciones consistentes en las muertes cardiovasculares (HR 0, 87) y en las hospitalizaciones por insuficiencia cardíaca (HR 0, 72).
  • Los beneficios fueron consistentes entre los subgrupos de fracción de eyección y los entornos de atención.

Conclusiones:

  • Los inhibidores de SGLT2 disminuyen la mortalidad cardiovascular y las hospitalizaciones por insuficiencia cardíaca en una amplia población de pacientes.
  • Estos medicamentos son una terapia básica para la insuficiencia cardíaca, independientemente de la fracción de eyección.
  • La evidencia apoya los inhibidores de SGLT2 como un tratamiento fundamental para todos los tipos de insuficiencia cardíaca.